<DOC>
	<DOCNO>NCT01527474</DOCNO>
	<brief_summary>This 8-week , open-label trial evaluate efficacy escitalopram monotherapy treatment patient postpartum depression ( PPD ) . The acute phase study consist 8 week treatment phase . Treatment eligible participant initiate dose 10mg/day adjust study clinician base presence depressive symptom side effect maximum 20mg/day . Study objectives : 1. investigate efficacy escitalopram treatment PPD . 2. assess effect escitalopram patient quality life .</brief_summary>
	<brief_title>Escitalopram Treatment Postpartum Depression</brief_title>
	<detailed_description>Major Depression Postpartum Onset ( PPD ) chronic relapse illness affect maternal mood also baby family . Therefore , critical aim timely intervention diagnosis make . Studies show antidepressant medication effective treatment moderate severe PPD . Common reason noncompliance discontinuation antidepressant medication postpartum period side effect associate different antidepressant . To choose antidepressant medication proven efficacy tolerable side effect profile key order maximize adherence pharmacotherapy . A number study publish highlight efficacy escitalopram treatment Major Depressive Disorder ( MDD ) . However , research date investigate effectiveness escitalopram treatment PPD . Based upon preliminary clinical observation tertiary care program ( Provincial Reproductive Mental Health Program ) postpartum depress population frequently treat antidepressant medication , compliance escitalopram impressive . Therefore , propose conduct open-label study escitalopram postpartum depress , non-lactating mother confirm clinical observation . Hypotheses : ) Escitalopram effective treatment Postpartum Depression ii ) Escitalopram effective increase quality life participant .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression , Postpartum</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>female age 19 40 year age give birth last 6 month currently breastfeed meet criterion Major Depressive Disorder per Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV TR ) MontgomeryAsberg Depression Rating Scale ( MADRS ) score great equal 25 enrolment able read write English sign write informed consent participate study . significant risk suicide accord investigator 's opinion present score 5 great item 10 ( suicidal thought ) MADRS meet DSMIVTR criterion past current manic hypomanic episode , past current psychotic symptom disorder , and/or history drug alcohol abuse/dependence within last 6 month use follow disallow recent concomitant medication within specified time period antidepressant drug use augmentation antidepressant action within last 2 week ( 5 week fluoxetine ) prior baseline , benzodiazepine anxiolytic within last week prior baseline , nonbenzodiazepine hypnotic within last week prior baseline , oral antipsychotic within 2 week depot antipsychotic within 6 month prior baseline , serotonergic medicinal product ( example triptans , tryptophan , tramadol ) within last week prior baseline , psychoactive herbal remedy ( example St. Johns Wort , kava kava , valerian , gingko biloba ) within last 2 week prior baseline , drug potential psychotropic effect within last 2 week prior baseline , anticonvulsant drug within last 2 week prior baseline , investigational product within 3 month prior baseline currently receive formal cognitive behavioural therapy , systematic psychotherapy , plan initiate therapy study current depressive symptom patient consider investigator resistant two wellconducted antidepressant treatment least 6 week duration serious illness serious sequela thereof , include liver renal insufficiency , cardiovascular , pulmonary , gastrointestinal , endocrine , neurological ( include epilepsy ) , infectious , neoplastic , metabolic disturbance ( history disease condition stable least one year judge investigator render inclusion unsafe interfere patient 's participation study , patient may include . )</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>postpartum</keyword>
	<keyword>postpartum depression</keyword>
	<keyword>PPD</keyword>
	<keyword>escitalopram</keyword>
</DOC>